Alberto Calvo-Hernando

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.

WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.

Journal: Oncotarget

Published: July 21, 2026

Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 08, 2026

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.

Journal: Future oncology (London, England)

Published: March 04, 2026

Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy.

Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 12, 2026

Targeting Regulatory T Cells for Cancer Immunotherapy: Promises and Pitfalls.

Targeting Regulatory T Cells for Cancer Immunotherapy: Promises and Pitfalls.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 26, 2026

Targeting regulatory T cells for cancer immunotherapy: promises and pitfalls.

Targeting regulatory T cells for cancer immunotherapy: promises and pitfalls.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 26, 2026

Evolving landscape of targeted therapies in early phase clinical trials.

Evolving landscape of targeted therapies in early phase clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 04, 2026

Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response.

Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response.

Journal: Journal for immunotherapy of cancer

Published: November 30, 2025

Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies.

Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies.

Journal: Frontiers in immunology

Published: July 11, 2025

Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy.

Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 23, 2025

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.

Journal: Oncotarget

Published: June 17, 2025

Prognostic Factors in Sinonasal Cancers: A Multicenter Pooled Analysis.

Prognostic Factors in Sinonasal Cancers: A Multicenter Pooled Analysis.

Journal: The Laryngoscope

Published: April 04, 2025

Showing 1-12 of 35

Last Updated: 09/26/2026